• FDA rejects oral Type I diabetes drug pharmatimes
    March 27, 2019
    The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Sanofi’s type I diabetes drug, Zynquista (sotagliflozin).
PharmaSources Customer Service